Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bardelli

Showing results (101-110 of 281) with videos related to

Pageof 29
Sort By:
Molecular Cancer Therapeutics|June 16, 2005
Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cellsKurtis E Bachman, Jason Sager, Ian Cheong, et al.
Cancer Research|April 19, 2007
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinomaAsha Balakrishnan, Fonnet E Bleeker, Simona Lamba, et al.
Human Mutation|October 16, 2010
MET mutations in cancers of unknown primary origin (CUPs)Giulia M Stella, Silvia Benvenuti, Daniela Gramaglia, et al.
Oncotarget|June 2, 2015
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathwayAnnalisa Conti, Maria Teresa Majorini, Richard Elliott, et al.
European Radiology|March 21, 2020
Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should knowMarco Calandri, Giulia Siravegna, Steven M Yevich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2019
Plasma HER2 (<i>ERBB2</i>) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal CancerGiulia Siravegna, Andrea Sartore-Bianchi, Rebecca J Nagy, et al.
Plos One|February 17, 2016
CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
ESMO Open|October 26, 2017
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastasesGiulia Siravegna, Elena Geuna, Benedetta Mussolin, et al.
Plos One|April 21, 2017
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Plos One|October 27, 2018
Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Pageof 29

Showing results (101-110 of 281) with videos related to

Sort By:
Pageof 29
Molecular Cancer Therapeutics|June 16, 2005
Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cellsKurtis E Bachman, Jason Sager, Ian Cheong, et al.
Cancer Research|April 19, 2007
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinomaAsha Balakrishnan, Fonnet E Bleeker, Simona Lamba, et al.
Human Mutation|October 16, 2010
MET mutations in cancers of unknown primary origin (CUPs)Giulia M Stella, Silvia Benvenuti, Daniela Gramaglia, et al.
Oncotarget|June 2, 2015
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathwayAnnalisa Conti, Maria Teresa Majorini, Richard Elliott, et al.
European Radiology|March 21, 2020
Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should knowMarco Calandri, Giulia Siravegna, Steven M Yevich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2019
Plasma HER2 (<i>ERBB2</i>) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal CancerGiulia Siravegna, Andrea Sartore-Bianchi, Rebecca J Nagy, et al.
Plos One|February 17, 2016
CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
ESMO Open|October 26, 2017
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastasesGiulia Siravegna, Elena Geuna, Benedetta Mussolin, et al.
Plos One|April 21, 2017
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Plos One|October 27, 2018
Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Pageof 29